Market Closed - Nasdaq Copenhagen 16:20:00 14/06/2024 BST 5-day change 1st Jan Change
1,832 DKK +0.47% Intraday chart for Genmab A/S -5.57% -14.97%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT
Transcript : Genmab A/S - Special Call
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
Genmab A/S Reaffirms Financial Guidance for 2024 CI
Genmab A/S completed the acquisition of ProfoundBio, Inc. CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress CI
GENMAB : A good start to 2024; guidance unchanged Alphavalue
Genmab Posts Q1 Net Profit Surge; Revenue Jumps MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021. CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024. CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug DJ
Chart Genmab A/S
More charts
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,824 DKK
Average target price
2,464 DKK
Spread / Average Target
+35.09%
Consensus
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. News Genmab A/S
  5. Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW